Research Ethics, Resource Allocation, and Global Bioethics

Ethics in Medicine, Lecture 4. This lecture covers the ethical foundations of clinical research, institutional review processes, resource allocation frameworks, global bioethics, and the role of cultural values in medical ethics.

RESEARCH ETHICS FOUNDATIONS

The history of research ethics is shaped by major scandals involving exploitation of vulnerable participants. The Nuremberg Code (1947) emerged from the Nuremberg Doctors' Trial, which revealed Nazi human experimentation. Its ten principles include: voluntary consent is absolutely essential; research should benefit society; risks must be proportionate to anticipated benefits; participants may withdraw at any time.

The Declaration of Helsinki (1964, World Medical Association, revised multiple times to 2013) extends Nuremberg to non-therapeutic research: ethics committee review is required; research involving patients must be combined with appropriate care; the welfare of participants takes priority over scientific interest; post-trial access to beneficial treatments should be considered.

The Belmont Report (1979, National Commission for the Protection of Human Subjects, USA) articulated three foundational principles: (1) Respect for persons — individuals should be treated as autonomous agents; persons with diminished autonomy (children, prisoners, cognitively impaired) are entitled to additional protections. (2) Beneficence — maximise benefits and minimise harms to participants. (3) Justice — the benefits and burdens of research must be distributed fairly; it is unjust to enrol only disadvantaged populations in risky research while directing benefits to the privileged.

INSTITUTIONAL ETHICS COMMITTEES (IECs/IRBs)

Every clinical research study involving human participants requires independent ethical review before commencement. Institutional ethics committees (New Zealand Health and Disability Ethics Committees, HDECs; US Institutional Review Boards, IRBs) assess: scientific merit (poor-quality science that cannot answer the question is inherently unethical), risk-benefit ratio, informed consent procedures, participant selection and recruitment, data privacy and security, conflict of interest, and plans for participant withdrawal and adverse event monitoring.

Vulnerable populations require additional protections: children — parents/guardians provide consent; assent should be sought from children who are sufficiently mature; research must offer prospect of direct benefit or only minimal risk above standard of care. Prisoners — voluntariness is compromised by power imbalance; most research ethics frameworks restrict prisoner participation. Cognitively impaired — substitute consent required from a legal representative. Pregnant women — research on interventions affecting pregnancy requires separate consideration; historical exclusion has led to evidence gaps.

CLINICAL TRIALS ETHICS

The principle of equipoise: genuine clinical equipoise is the prerequisite for randomisation — the research community must have genuine uncertainty about which arm of the trial is superior. If there is already good evidence that one arm is better, randomisation is unethical because participants may be assigned to inferior treatment. This justifies withholding the experimental treatment from controls only when its superiority is genuinely uncertain.

Placebo use in clinical trials is ethically permissible when: (1) there is no effective existing treatment for the condition; or (2) for methodological reasons a placebo is necessary and withholding the established treatment will not cause serious or irreversible harm. Active-controlled (non-inferiority) trials comparing a new treatment against an established effective treatment are required when an established standard of care exists.

Stopping rules and Data Safety Monitoring Boards (DSMB): clinical trials should specify pre-defined stopping rules for harm (an experimental treatment causing significantly more harm than control) or benefit (early unequivocal evidence of superiority). An independent DSMB reviews interim data and makes recommendations — blinded researchers are protected from unblinding bias. Publication bias: selective publication of positive results distorts the evidence base; negative results have equal scientific value and should be published; trial registries (ClinicalTrials.gov, ANZCTR) require pre-registration to combat outcome switching.

RESOURCE ALLOCATION

Health systems face finite resources and must make allocation decisions. Four major ethical frameworks: (1) Egalitarian: everyone has an equal claim to healthcare resources regardless of other characteristics; first-come first-served; lottery. (2) Utilitarian: maximise total health benefit to the population; prioritise interventions that generate the most health gain per unit cost. (3) Prioritarian (prioritise the worst off first): give priority to those with the greatest need, regardless of whether they generate maximum benefit; reflects social solidarity. (4) Instrumental value: prioritise those who provide essential services (e.g., healthcare workers in a pandemic) because their survival enables others to survive.

Quality-Adjusted Life Year (QALY): one QALY represents one year of perfect health. Health states below perfect health have QALY weights between 0 (death) and 1 (perfect health). A QALY-based approach calculates the incremental cost-effectiveness ratio (ICER): cost per QALY gained. NICE (UK) applies a threshold of approximately £20,000-30,000 per QALY for funding decisions; above this, treatments are generally not funded unless there are special circumstances (end of life, rare diseases). PHARMAC (NZ) applies a similar cost-effectiveness framework, weighted by New Zealand's health system budget. QALY limitations: (1) values health states using population survey weights (EQ-5D) which may not reflect individual patients' values; (2) discriminates against people with disabilities or chronic illness (less QALY gain per treatment); (3) ignores distributive concerns — maximising QALYs across the population may concentrate resources on younger, healthier patients.

Pandemic resource allocation: COVID-19 forced explicit ventilator allocation policies. Key frameworks: multi-principle approaches combining short-term survival probability (SOFA score), life-years saved (long-term prognosis), lottery (equal priority within tiers), and priority for essential workers. Ethical challenges: who defines the criteria; how to avoid embedding racial and socioeconomic bias into scoring systems; transparency of decision-making.

GLOBAL BIOETHICS

Pharmaceutical access inequity: patent protection under the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights, WTO) grants pharmaceutical companies 20-year monopolies on new drugs, enabling cost recovery and profit. This creates profound inequity: HIV antiretroviral drugs costing thousands of dollars per year in high-income countries were inaccessible to sub-Saharan Africa in the 1990s. The Doha Declaration (2001) affirmed countries' rights to compulsory licensing — producing or importing generic versions of patented drugs in public health emergencies — enabling access to affordable ARVs. Vaccine nationalism (COVID-19): high-income countries pre-purchased vaccine supplies, delaying availability to low-income countries through COVAX. Ethical argument: global pandemic control requires global vaccine access — inequitable distribution prolongs pandemic and facilitates variant emergence.

Standard of care in developing-country trials: ethical controversy arises when sponsors from high-income countries conduct trials in low-income countries using placebo controls that would not be permissible in the sponsor's home country (because an effective treatment exists). The Declaration of Helsinki requires that participants receive at least the best currently available treatment globally — not only the local standard of care. Host-country versus universal standard debate continues.

CULTURAL COMPETENCE IN ETHICS

Western bioethics is founded on individual autonomy — the individual patient makes decisions about their own body. This model does not map universally. Collectivist cultures prioritise family decision-making: the family unit, not only the individual, is the locus of decision-making; sharing a diagnosis with a patient without family consent may be considered inappropriate in some cultural frameworks (e.g., some East Asian and Middle Eastern cultural contexts). Clinicians should explore patients' preferences for information disclosure and family involvement without stereotyping.

Maori clinical ethics: whanau-centred decision-making — major health decisions involve the extended family; tikanga Maori practices at end of life include karakia (prayer/incantation), the presence of whanau, and return of the body (tangihanga); respecting these practices is part of culturally safe care and consistent with Treaty obligations. Clinicians should enquire about cultural and spiritual needs and involve Maori health navigators.

Social media and professional ethics: clinicians must not post patient information online (explicit or implicit identifiers); social media boundaries are part of professional codes; medical misinformation requires clinicians to actively counter false information in a manner consistent with professional obligations.